Urinary Marker Profiles in Heart Failure with Reduced Versus Preserved Ejection Fraction
-
Published:2023-02-16
Issue:
Volume:
Page:
-
ISSN:1937-5387
-
Container-title:Journal of Cardiovascular Translational Research
-
language:en
-
Short-container-title:J. of Cardiovasc. Trans. Res.
Author:
Streng Koen W.ORCID, Hillege Hans L., ter Maaten Jozine M., van Veldhuisen Dirk J., Dickstein Kenneth, Samani Nilesh J., Ng Leong L., Metra Marco, Filippatos Gerasimos S., Ponikowski Piotr, Zannad Faiez, Anker Stefan D., van der Meer Peter, Lang Chim C., Voors Adriaan A., Damman Kevin
Abstract
Abstract
Background
Recent data suggest different causes of renal dysfunction between heart failure with reduced (HFrEF) versus preserved ejection fraction (HFpEF). We therefore studied a wide range of urinary markers reflecting different nephron segments in heart failure patients.
Methods
In 2070, in chronic heart failure patients, we measured several established and upcoming urinary markers reflecting different nephron segments.
Results
Mean age was 70 ± 12 years, 74% was male and 81% (n = 1677) had HFrEF. Mean estimated glomerular filtration rate (eGFR) was lower in patients with HFpEF (56 ± 23 versus 63 ± 23 ml/min/1.73 m2, P = 0.001). Patients with HFpEF had significantly higher values of NGAL (58.1 [24.0–124.8] versus 28.1 [14.6–66.9] μg/gCr, P < 0.001) and KIM-1 (2.28 [1.49–4.37] versus 1.79 [0.85–3.49] μg/gCr, P = 0.001). These differences were more pronounced in patients with an eGFR > 60 ml/min/1.73m2.
Conclusions
HFpEF patients showed more evidence of tubular damage and/or dysfunction compared with HFrEF patients, in particular when glomerular function was preserved.
Funder
Hartstichting FP7 Ideas: European Research Council
Publisher
Springer Science and Business Media LLC
Subject
Genetics (clinical),Cardiology and Cardiovascular Medicine,Pharmaceutical Science,Genetics,Molecular Medicine
Reference39 articles.
1. Damman K, Voors AA, Navis G, van Veldhuisen DJ, Hillege HL. The cardiorenal syndrome in heart failure. Prog Cardiovasc Dis. 2011;54:144–53. 2. Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, Hampton JR, van Veldhuisen DJ. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203–10. 3. Damman K, Valente MA, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35:455–69. 4. Streng KW, Nauta JF, Hillege HL, Anker SD, Cleland JG, Dickstein K, Filippatos G, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Zannad F, Damman K, van dM, Voors AA. Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. Int J Cardiol. 2018. 5. Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11:507–15.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Baseline urinary osteopontin levels are associated with the improvement of metabolic syndrome;Nutrition, Metabolism and Cardiovascular Diseases;2024-08 2. Best Paper of the Year 2023;Journal of Cardiovascular Translational Research;2024-02 3. Heart Failure: Is There an Ideal Biomarker?;Reviews in Cardiovascular Medicine;2023-11-09
|
|